Recurrent AA Amyloidosis After Renal Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

54 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-02-29

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

End-stage renal disease related to AA amyloidosis is well characterized but there is limited data concerning patient and graft outcomes after renal transplantation. The aim of this study is to evaluate the clinical features of, and risk factors for recurrent AA amyloidosis, as well as the effects of these factors on the ultimate outcome of renal allografts.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Recurrent Glomerulonephritis After Renal Transplantation

NCT02700516

Glomerulonephritis

COMPLETED

Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection

NCT04367610

Antibody-mediated Rejection Kidney Transplant Rejection Graft Loss

COMPLETED

Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Liver Transplantation

NCT02080065

Renal Function Liver Transplantation

COMPLETED

Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients

NCT00547040

Renal Transplant Atherosclerosis Arterial Stiffness

COMPLETED

Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis

NCT01001065

Renal Transplantation

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

AA amyloidosis is a rare but serious complication of several chronic inflammatory diseases including recurrent hereditary periodic fever syndromes. Although end-stage renal disease related to AA amyloidosis is well characterized, there is limited data concerning patient and graft outcomes after renal transplantation, with most of the findings reported from small series. Recurrence of amyloidosis in the renal allograft might be underdiagnosed, assessing graft and patient outcomes in larger study groups will bring better understanding and new strategies in daily practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

AA Amyloidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Recurrent AA amyloidosis

Renal transplant recipients with biopsy-confirmed AA amyloidosis in the renal allograft

No interventions assigned to this group

Control group 1

Renal transplant recipients whose primary diseases are amyloidosis with no clinical or laboratory signs of recurrence in the renal allograft

No interventions assigned to this group

Control group 2

Renal transplant recipients whose primary diseases are other than amyloidosis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Renal transplantation recipients whose primary renal disease is AA amyloidosis; patients with allograft biopsy-confirmed AA amyloidosis (for study group) and patients with no clinical or laboratory signs of recurrence in the renal allograft (for control group 1)
* Renal transplantation recipients whose primary diseases are other than AA amyloidosis (for control group 2)